Loading
What changed between revision 1 and revision 2, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/targeted-drug-delivery.md — the filesystem corpus, unchanged. Not an edit.
12.8 kB
Revision 1
Revision 2
lines 8–14 → 8–147 unchanged lines not shown
categories: ["nanomedicine"]categories: ["nanomedicine"]tags: ["nanomedicine", "drug delivery", "oncology", "antibody-drug conjugates", "pharmacokinetics", "nanoparticles"]tags: ["nanomedicine", "drug delivery", "oncology", "antibody-drug conjugates", "pharmacokinetics", "nanoparticles"]summary: "The engineering of carriers and conjugates that concentrate a drug where it is needed, a field whose clinical successes have come from chemistry rather than from nanoparticle targeting."summary: "The engineering of carriers and conjugates that concentrate a drug where it is needed, a field whose clinical successes have come from chemistry rather than from nanoparticle targeting."updated: "2026-07-27"updated: "2026-10-29"humanEvidence: "Antibody-drug conjugates, sugar-conjugated siRNAs and reformulated carriers are approved and in routine use in patients; no approved nanomedicine's benefit is clearly attributable to EPR targeting."humanEvidence: "Antibody-drug conjugates, sugar-conjugated siRNAs and reformulated carriers are approved and in routine use in patients; no approved nanomedicine's benefit is clearly attributable to EPR targeting."access: "Approved conjugates and reformulated carriers are prescribed routinely in oncology and rare disease at specialty-biologic prices; carriers targeted to tissues outside the liver exist only in research."access: "Approved conjugates and reformulated carriers are prescribed routinely in oncology and rare disease at specialty-biologic prices; carriers targeted to tissues outside the liver exist only in research."reversibility: "reversible"reversibility: "reversible"lines 21–27 → 21–276 unchanged lines not shown
"rows": [ "rows": [ { "label": "Origin of the idea", "value": "Paul Ehrlich's 'magic bullet', c. 1900" }, { "label": "Origin of the idea", "value": "Paul Ehrlich's 'magic bullet', c. 1900" }, { "label": "First approved nanocarrier", "value": "Liposomal doxorubicin, 1995" }, { "label": "First approved nanocarrier", "value": "Liposomal doxorubicin, 1995" }, { "label": "Dominant modality", "value": "Antibody–drug conjugates" }, { "label": "Dominant modality", "value": "Antibody-drug conjugates" }, { "label": "Typical tumour delivery", "value": "Under 1% of injected dose" }, { "label": "Typical tumour delivery", "value": "Under 1% of injected dose" }, { "label": "Default destination", "value": "Liver and spleen" }, { "label": "Default destination", "value": "Liver and spleen" }, { "label": "Key failure mode", "value": "Clearance by phagocytes" }, { "label": "Key failure mode", "value": "Clearance by phagocytes" },lines 36–42 → 36–428 unchanged lines not shown
[[ { "value": "0.7%", "label": "Median share of injected nanoparticle dose reaching a solid tumour", "note": "across a decade of published studies surveyed in 2016" }, { "value": "0.7%", "label": "Median share of injected nanoparticle dose reaching a solid tumour", "note": "across a decade of published studies surveyed in 2016" }, { "value": "1995", "label": "First approved nanoparticle drug", "note": "liposomal doxorubicin, which reduced cardiac toxicity without improving survival in most settings" }, { "value": "1995", "label": "First approved nanoparticle drug", "note": "liposomal doxorubicin, which reduced cardiac toxicity without improving survival in most settings" }, { "value": "12+", "label": "Antibody–drug conjugates approved worldwide", "note": "more than a dozen as of 2026; the modality that delivered on the targeting premise" } { "value": "12+", "label": "Antibody-drug conjugates approved worldwide", "note": "more than a dozen as of 2026; the modality that delivered on the targeting premise" }]]`````` lines 46–60 → 46–603 unchanged lines not shown
Passive targeting relies on where a particle goes by default. Carriers between roughly 10 and 200 nanometres circulate longer than free drug, avoid renal filtration, and accumulate preferentially in tissues with leaky vasculature. Tumours were long thought to be such tissues: the enhanced permeability and retention effect, described by Matsumura and Maeda in 1986, holds that fenestrated tumour vessels let macromolecules out and poor lymphatic drainage keeps them there.[^matsumura1986] EPR became the organising rationale for cancer nanomedicine.Passive targeting relies on where a particle goes by default. Carriers between roughly 10 and 200 nanometres circulate longer than free drug, avoid renal filtration, and accumulate preferentially in tissues with leaky vasculature. Tumours were long thought to be such tissues: the enhanced permeability and retention effect, described by Matsumura and Maeda in 1986, holds that fenestrated tumour vessels let macromolecules out and poor lymphatic drainage keeps them there.[^matsumura1986] EPR became the organising rationale for cancer nanomedicine. Active targeting attaches a ligand — an antibody, an aptamer, a peptide, a sugar — that binds a receptor enriched on the target cell. The intuitive picture is that the ligand steers the carrier. It does not. Studies comparing antibody-targeted and untargeted liposomes found that targeting made no difference to how much drug reached the tumour; what it changed was how much of the drug that arrived got inside cells rather than sitting in the interstitium.[^kirpotin2006] Targeting improves uptake at the destination; it does not improve navigation.Active targeting attaches a ligand (an antibody, an aptamer, a peptide, a sugar) that binds a receptor enriched on the target cell. The intuitive picture, in which the ligand steers the carrier, is wrong. Studies comparing antibody-targeted and untargeted liposomes found that targeting made no difference to how much drug reached the tumour; what it changed was how much of the drug that arrived got inside cells rather than sitting in the interstitium.[^kirpotin2006] Targeting improves uptake at the destination; it does not improve navigation. Clearance dominates both. Any particle entering blood adsorbs plasma proteins within seconds, forming a corona that determines its biological identity more than its engineered surface does.[^cedervall2007] Opsonised particles are removed by macrophages of the liver and spleen. Polyethylene glycol coatings slow this, and pre-existing anti-PEG antibodies, common in the general population, can accelerate it again.Clearance dominates both. Any particle entering blood adsorbs plasma proteins within seconds, forming a corona that determines its biological identity more than its engineered surface does.[^cedervall2007] Opsonised particles are removed by macrophages of the liver and spleen. Polyethylene glycol coatings slow this, and pre-existing anti-PEG antibodies, common in the general population, can accelerate it again. ## The reckoning over EPR## The reckoning over EPR In 2016 a survey of a decade of published animal studies found that the median proportion of an injected nanoparticle dose reaching a solid tumour was about 0.7 percent.[^wilhelm2016] The number was contested — critics argued that percentage of injected dose is the wrong metric, since what matters is concentration at the target relative to toxicity elsewhere — but the central point survived the argument: the accumulation the field had assumed was an order of magnitude smaller than advertised.In 2016 a survey of a decade of published animal studies found that the median proportion of an injected nanoparticle dose reaching a solid tumour was about 0.7 percent.[^wilhelm2016] The number was contested. Critics argued that percentage of injected dose is the wrong metric, since what matters is concentration at the target relative to toxicity elsewhere, but the central point survived the argument: the accumulation the field had assumed was an order of magnitude smaller than advertised. A 2020 study then challenged the mechanism itself. Using models in which endothelial gaps could be counted, it concluded that the great majority of nanoparticles entering tumours did so by active transport through endothelial cells rather than by leaking through gaps between them.[^sindhwani2020] If entry is an energy-dependent cellular process rather than passive diffusion through holes, then the design rules derived from EPR — optimise size and circulation time, wait for leakage — were aimed at the wrong variable.A 2020 study then challenged the mechanism itself. Using models in which endothelial gaps could be counted, it concluded that the great majority of nanoparticles entering tumours did so by active transport through endothelial cells rather than by leaking through gaps between them.[^sindhwani2020] If entry is an energy-dependent cellular process rather than passive diffusion through holes, then the design rules derived from EPR (optimise size and circulation time, wait for leakage) were aimed at the wrong variable. EPR is also far more variable in humans than in the mouse xenografts where it was characterised. Rodent tumours grow fast, are highly vascularised, and are large relative to the animal; human tumours are heterogeneous, often fibrotic, and frequently have high interstitial pressure that opposes convective entry.EPR is also far more variable in humans than in the mouse xenografts where it was characterised. Rodent tumours grow fast, are highly vascularised, and are large relative to the animal; human tumours are heterogeneous, often fibrotic, and frequently have high interstitial pressure that opposes convective entry. lines 63–81 → 63–812 unchanged lines not shown
## What actually worked## What actually worked Antibody–drug conjugates are the modality that delivered. An antibody against a tumour antigen carries a cytotoxic payload too potent to be given systemically, joined by a linker designed to hold in blood and release inside the cell. Gemtuzumab ozogamicin was approved in 2000, withdrawn in 2010 over toxicity and lack of demonstrated benefit, and reapproved in 2017 at a lower, fractionated dose — a history that illustrates how narrow the therapeutic window is. Brentuximab vedotin, ado-trastuzumab emtansine, and trastuzumab deruxtecan followed, the last extending benefit to tumours expressing only low levels of its target because the released payload diffuses into neighbouring cells.Antibody-drug conjugates are the modality that delivered. An antibody against a tumour antigen carries a cytotoxic payload too potent to be given systemically, joined by a linker designed to hold in blood and release inside the cell. Gemtuzumab ozogamicin was approved in 2000, withdrawn in 2010 over toxicity and lack of demonstrated benefit, and reapproved in 2017 at a lower, fractionated dose, a history that illustrates how narrow the therapeutic window is. Brentuximab vedotin, ado-trastuzumab emtansine, and trastuzumab deruxtecan followed, the last extending benefit to tumours expressing only low levels of its target because the released payload diffuses into neighbouring cells. Conjugation to a sugar ligand achieved something similar for RNA drugs. Attaching a triantennary N-acetylgalactosamine group to a small interfering RNA directs it to the asialoglycoprotein receptor, which hepatocytes display in enormous numbers. The result is subcutaneous dosing, liver-specific silencing, and durable effect from infrequent injections — the most complete example of receptor-directed delivery in medicine.Conjugation to a sugar ligand achieved something similar for RNA drugs. Attaching a triantennary N-acetylgalactosamine group to a small interfering RNA directs it to the asialoglycoprotein receptor, which hepatocytes display in enormous numbers. The result is subcutaneous dosing, liver-specific silencing, and durable effect from infrequent injections. It is the most complete example of receptor-directed delivery in medicine. Nanoparticle carriers succeeded where the goal was reformulation rather than targeting. Liposomal doxorubicin reduced cardiotoxicity. Albumin-bound paclitaxel eliminated a toxic solvent. [[lipid-nanoparticles]] made mRNA vaccines and the first systemic in vivo genome-editing therapies possible, and they work because they go to the liver reliably, not because they go anywhere selectively.Nanoparticle carriers succeeded where the goal was reformulation rather than targeting. Liposomal doxorubicin reduced cardiotoxicity. Albumin-bound paclitaxel eliminated a toxic solvent. [[lipid-nanoparticles]] made mRNA vaccines and the first systemic in vivo genome-editing therapies possible, and they work because they go to the liver reliably, not because they go anywhere selectively. What none of these resembles is a carrier that navigates. The addressable containers of [[dna-nanotechnology]] come closest to conditional release on a molecular signal, and they have reached mice rather than patients. Where cells must be modified precisely, the field has generally moved the targeting problem out of the body altogether: [[casgevy]] and other ex vivo therapies remove the cells, edit them in a facility, and put them back, which is expensive and immunologically demanding but sidesteps delivery entirely.None of these resembles a carrier that navigates. The addressable containers of [[dna-nanotechnology]] come closest to conditional release on a molecular signal, and they have reached mice rather than patients. Where cells must be modified precisely, the field has generally moved the targeting problem out of the body altogether: [[casgevy]] and other ex vivo therapies remove the cells, edit them in a facility, and put them back, which is expensive and immunologically demanding but sidesteps delivery entirely. ## Limitations## Limitations The liver is the recurring problem. Its fenestrated endothelium and resident macrophages take up most of what circulates, which is convenient for hepatic targets and an obstacle for everything else. Reformulating a particle to shift its protein corona can redirect it toward lung or spleen, and antibody-decorated particles have reached specific cell types in animals, but no carrier has been approved on the strength of selective delivery to a tissue outside the liver.The liver is the recurring problem. Its fenestrated endothelium and resident macrophages take up most of what circulates, which is convenient for hepatic targets and an obstacle for everything else. Reformulating a particle to shift its protein corona can redirect it toward lung or spleen, and antibody-decorated particles have reached specific cell types in animals, but no carrier has been approved on the strength of selective delivery to a tissue outside the liver. The brain is harder still. The blood–brain barrier excludes almost all particles; the approaches with the best evidence use receptor-mediated transcytosis through the transferrin receptor, or temporary mechanical opening of the barrier with focused ultrasound and injected microbubbles, the same modality used for the non-thermal brain stimulation covered in [[non-invasive-neuromodulation]]. Both are in clinical development rather than routine use.The brain is harder still. The blood-brain barrier excludes almost all particles; the approaches with the best evidence use receptor-mediated transcytosis through the transferrin receptor, or temporary mechanical opening of the barrier with focused ultrasound and injected microbubbles, the same modality used for the non-thermal brain stimulation covered in [[non-invasive-neuromodulation]]. Both are in clinical development rather than routine use. Even at the target, a carrier must escape the endosome. For nucleic acid cargoes this is the dominant inefficiency, with only a small percentage of internalised material reaching the cytosol.Even at the target, a carrier must escape the endosome. For nucleic acid cargoes this is the dominant inefficiency, with only a small percentage of internalised material reaching the cytosol. lines 85–93 → 85–933 unchanged lines not shown
## Outlook## Outlook The lesson the field draws from its own record is that delivery is not a finishing step applied to a finished drug — it determines what drugs are possible. Genome editing is the clearest case: the set of diseases addressable by [[crispr-cas9]] and [[base-editing]] as of 2026 is essentially the set of diseases whose causal gene is expressed in hepatocytes, because that is where the carriers go. Extending editing to muscle, immune cells, or the central nervous system is a delivery problem, not an editing one, and the same is true of proposals such as [[gene-therapy-for-aging]] or the systemic administration of [[senolytics]].The lesson the field draws from its own record is that delivery determines what drugs are possible rather than being a finishing step applied to a finished drug. Genome editing is the clearest case: the set of diseases addressable by [[crispr-cas9]] and [[base-editing]] as of 2026 is essentially the set of diseases whose causal gene is expressed in hepatocytes, because that is where the carriers go. Extending editing to muscle, immune cells, or the central nervous system is a delivery problem, not an editing one, and the same is true of proposals such as [[gene-therapy-for-aging]] or the systemic administration of [[senolytics]]. Two directions look most likely to change that. Engineered capsids of the kind described in [[aav-vectors]], and cell-type-selective lipids, are converging on the ability to specify a destination tissue at formulation time, an incremental route that has already produced organ-selective particles in animals and that would widen the reach of [[somatic-gene-therapy]] more than any change to the editing enzymes themselves. Cell-based carriers — red cell membranes, macrophages, engineered bacteria — borrow biology's own trafficking rather than trying to replicate it, and shade into the externally guided devices covered in [[microrobots-in-medicine]]. Neither approach resembles the autonomous targeting machine imagined in [[medical-nanorobots]], and the history of this field is a long argument that the imagined version underrates how thoroughly the body sorts what enters it.Two directions look most likely to change that. Engineered capsids of the kind described in [[aav-vectors]], and cell-type-selective lipids, are converging on the ability to specify a destination tissue at formulation time, an incremental route that has already produced organ-selective particles in animals and that would widen the reach of [[somatic-gene-therapy]] more than any change to the editing enzymes themselves. Cell-based carriers (red cell membranes, macrophages, engineered bacteria) borrow biology's own trafficking rather than trying to replicate it, and shade into the externally guided devices covered in [[microrobots-in-medicine]]. Neither approach resembles the autonomous targeting machine imagined in [[medical-nanorobots]], and the history of this field is a long argument that the imagined version underrates how thoroughly the body sorts what enters it. ## See also## See also removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
98 lines are the same in both revisions, and 46 of them are not shown. Neither revision here is necessarily the current article — read Targeted drug delivery for the text this wiki stands behind today.